Results 41 to 50 of about 212,315 (369)
Current clinician perspective on non-vitamin K antagonist oral anticoagulant use in challenging clinical cases. [PDF]
, 2020 OBJECTIVE: The evolution of non-vitamin K antagonist anticoagulants (NOACs) has changed the horizon of stroke prevention in atrial fibrillation (SPAF).
Acar, RD +12 more
core +1 more source
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
New England Journal of Medicine, 2013 BACKGROUND Whether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear. METHODS In a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous ...
H. Büller +12 more
semanticscholar +1 more source
Coexisting Cardiac and Hematologic Disorders. [PDF]
, 2016 Patients with concomitant cardiac and hematologic disorders presenting for noncardiac surgery are challenging. Anemic patients with cardiac disease should be approached in a methodical fashion.
Goldhammer, Jordan E., Kohl, Benjamin A.
core +3 more sources
Warfarin Pharmacogenetics [PDF]
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2008 Significant interest in the pharmacogenetics of warfarin therapy has been triggered with the recent package insert update that highlights the potential role of pharmacogenetics in improving the safety and effectiveness of warfarin. We review the evidence of the influence of the two key genes of interest, the cytochrome P450 2C9 gene, CYP2C9, and the ...
Nita A, Limdi, David L, Veenstra
openaire +2 more sources
Evaluation of pharmacokinetics of warfarin from validated pharmacokinetic-pharmacodynamic model
ADMET and DMPK, 2021 Background: Pharmacokinetics of warfarin has not been described in our population. We derived the pharmacokinetic parameters from a validated pharmacokinetic-pharmacodynamic model. Methods: Patients receiving warfarin for at least 6 months were recruited
Kannan Sridharan +2 more
doaj +1 more source
Global Thrombosis Test - a possible monitoring system for the effects and safety of dabigatran [PDF]
, 2015 © Otsui et al. 2015BACKGROUND: Dabigatran is an alternative to warfarin (WF) for the thromboprophylaxis of stroke in patients with non-valvular atrial fibrillation (NVAF). The advantage of dabigatran over WF is that monitoring is not required; however, a
Gorog, Diana A +8 more
core +2 more sources
JAMA Neurology, 2019 Key Points Question Is dabigatran etexilate or dose-adjusted warfarin efficacious and safe to use in preventing the recurrence of venous thrombotic events among patients with cerebral venous thrombosis? Findings In this exploratory randomized, open-label
J. Ferro +14 more
semanticscholar +1 more source
Major Outcomes in Atrial Fibrillation Patients with One Risk Factor: Impact of Time in Therapeutic Range [PDF]
, 2016 BACKGROUND: The benefits and harms of oral anticoagulation (OAC) therapy in patients with only one stroke risk factor (i.e. CHA2DS2-VASc= 1 in males, or 2 in females) has been subject of debate.
Lip, Gregory Y. H., Proietti, Marco
core +2 more sources
British medical journal, 2018 Objective To investigate the associations between direct oral anticoagulants (DOACs) and risks of bleeding, ischaemic stroke, venous thromboembolism, and all cause mortality compared with warfarin. Design Prospective open cohort study. Setting UK general
Y. Vinogradova +3 more
semanticscholar +1 more source
Incomplete Resolution of Deep Vein Thromboses during Rivaroxaban Therapy. [PDF]
, 2017 We present the case of a patient with a deep vein thrombosis (DVT) who failed rivaroxaban therapy. Our patient initially presented with left lower extremity edema, erythema, and pain.
Adashek, Jacob +6 more
core +5 more sources